Larry Ramer

Larry Ramer

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Massive, Far-Reaching Partnerships Make Arrival Stock Look Great Here

Arrival has made big deals with Uber and UPS, leaving ARVL stock very well-positioned to outperform over the longer term.

4 Hot Cyclical Stocks to Buy Now

Here are four of the best cyclical stocks that are heating up and poised to rally much further. They are all worth buying at this point.

Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness

The patent waiver matter will likely prove to be a "nonissue," while NVAX stock has many upcoming, positive catalysts.

Why It’s Still Not Time to Buy Snowflake Stock

SNOW stock is still trading at an enormous valuation, and the company's guidance may be negatively affected by the reopening trend.

AT&T Is Ailing, and Investors Should Unload T Stock

Going forward, AT&T is facing many risks, including accelerated cord cutting and reduced post-pandemic spending on hardware. T stock is a sell.

Uncertainties, Unknowns Make Skillz Stock Too Risky

Due to esports' relatively low popularity and the high valuation of SKLZ stock, the shares are unattractive at these levels.

Buyers of Plug Power Stock Won’t Wind Up Swimming Naked

Boosted by strong support from partners and governments, PLUG stock will climb much higher over the longer term.

BlackBerry by Any Other Name Would Have a Much Higher Valuation

BB stock is artificially low only because of its name and past failures. Soon a few strong catalysts will change that situation.

Why Ocugen Stock Continues to Be a Great Short Opportunity

No U.S. government official has made positive comments about approving Covaxin and the Covaxin trials do not seem to meet the FDA's preferences. OCGN stock is a short.

3 Stock Market Bubble Stocks to Avoid

There's a dispute about whether we are in a stock market bubble, but no one argues that many stocks have reached bubble territory.